Purple Innovation Inc
For the period ended Sep 30, 2024. Filed Nov 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 4, 2024
PRPL$1.80-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(unaudited – in thousands)
| Class A · Class B · Additional · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Common Stock · Common Stock · Paid-in · Accumulated · Stockholders’ · Noncontrolling · Total | |||||||||
| Shares | Par Value | Shares | Par Value | Capital | Deficit | Equity | Interest | Equity | |
| Balance – December 31, 2023 | 105,507 | $11 | 205 | $— | $591,380 | $(475,969) | $115,422 | $185 | $115,607 |
| Net loss | — | — | — | — | — | (50,217) | (50,217) | (51) | (50,268) |
| Stock-based compensation | — | — | — | — | 492 | — | 492 | — | 492 |
| Issuance of stock for Intellibed acquisition | 1,500 | — | — | — | — | — | — | — | — |
| Issuance of stock under equity compensation plans | 473 | — | — | — | (115) | — | (115) | — | (115) |
| Impact of transactions affecting NCI | — | — | — | — | (33) | — | (33) | 33 | — |
| Balance – March 31, 2024 | 107,480 | $11 | 205 | $— | $591,724 | $(526,186) | $65,549 | $167 | $65,716 |
| Net income (loss) | — | — | — | — | — | 27 | 27 | (36) | (9) |
| Stock-based compensation | — | — | — | — | 825 | — | 825 | — | 825 |
| Issuance of common stock under equity compensation plans | 23 | — | — | — | — | — | — | — | — |
| Impact of transactions affecting NCI | — | — | — | — | (8) | — | (8) | 8 | — |
| Balance – June 30, 2024 | 107,503 | $11 | 205 | $— | $592,541 | $(526,159) | $66,393 | $139 | $66,532 |
| Net loss | — | — | — | — | — | (39,228) | (39,228) | (82) | (39,310) |
| Stock-based compensation | — | — | — | — | 791 | — | 791 | — | 791 |
| Exchange of stock | 13 | — | (13) | — | — | — | — | — | — |
| Impact of transactions affecting NCI | — | — | — | — | 11 | — | 11 | (11) | — |
| Balance – September 30, 2024 | 107,516 | $11 | 192 | $— | $593,343 | $(565,387) | $27,967 | $46 | $28,013 |
| Class A · Class B · Additional · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Common Stock · Common Stock · Paid-in · Accumulated · Stockholders’ · Noncontrolling · Total | |||||||||
| Shares | Par Value | Shares | Par Value | Capital | Deficit | Equity | Interest | Equity | |
| Balance – December 31, 2022 | 91,380 | $9 | 448 | $— | $529,466 | $(355,212) | $174,263 | $908 | $175,171 |
| Net loss | — | — | — | — | — | (25,933) | (25,933) | (119) | (26,052) |
| Stock-based compensation | — | — | — | — | 1,192 | — | 1,192 | — | 1,192 |
| Issuance of stock under equity compensation plans | 265 | — | — | — | — | — | — | — | — |
| Issuance of stock upon underwritten offering, net of costs | 13,400 | 2 | — | — | 57,198 | — | 57,200 | — | 57,200 |
| Impact of transactions affecting NCI | — | — | — | — | (103) | — | (103) | 103 | — |
| Balance – March 31, 2023 | 105,045 | $11 | 448 | $— | $587,753 | $(381,145) | $206,619 | $892 | $207,511 |
| Net loss | — | — | — | — | — | (40,487) | (40,487) | (167) | (40,654) |
| Stock-based compensation | — | — | — | — | 1,661 | — | 1,661 | — | 1,661 |
| Exchange of stock | 20 | — | (20) | — | — | — | — | — | — |
| Proportional Representation Preferred Linked Stock redemption fee | — | — | — | — | (105) | — | (105) | — | (105) |
| Additional costs associated with underwritten public stock offering | — | — | — | — | (201) | — | (201) | — | (201) |
| Issuance of stock under equity compensation plans | 258 | — | — | — | — | — | — | — | — |
| Impact of transactions affecting NCI | — | — | — | — | 37 | — | 37 | (37) | — |
| Balance – June 30, 2023 | 105,323 | $11 | 428 | $— | $589,145 | $(421,632) | $167,524 | $688 | $168,212 |
| Net loss | — | — | — | — | — | (36,004) | (36,004) | (131) | (36,135) |
| Stock-based compensation | — | — | — | — | 939 | — | 939 | — | 939 |
| Exchange of stock | 10 | — | (10) | — | — | — | — | — | — |
| Impact of transactions affecting NCI | — | — | — | — | 12 | — | 12 | (12) | — |
| Balance – September 30, 2023 | 105,333 | $11 | 418 | $— | $590,096 | $(457,636) | $132,471 | $545 | $133,016 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.